GordonMD Group Invests $12.2M in Pyxis Oncology's $110M Offering
PYXS has more than doubled off its 52-week low of $1.03 on elevated volume (2.1× avg).
Summary
GordonMD entities invested $12.2 million in Pyxis Oncology's $110 million offering, acquiring 13.06 million shares and 7.55 million warrants at $2.90 per unit.
Key Events · Ownership and Investor Activity · PYXS
-
GordonMD Invests $12.2M in Offering
GordonMD Global Investments and affiliates acquired 13,063,766 shares and 7,546,766 warrants at $2.90 per unit, totaling $12.19 million.
-
Stake Rises to 15.5M Shares
Post-transaction holdings reach 15,541,909 shares, consolidating the group's position as a major shareholder.
-
Warrants Contingent on Charter Amendment
The 7.55 million warrants carry a $3.50 exercise price and cannot be exercised until shareholders approve an increase in authorized shares.
-
Follows $110M Offering Close
The purchase occurred on October 1, 2026, the same day Pyxis Oncology closed its $110 million public offering with $102.8 million in net proceeds.
Analysis · PYXS · Life Sciences
GordonMD Global Investments and affiliated entities acquired 13.06 million shares and 7.55 million warrants in Pyxis Oncology's public offering, a $12.2 million commitment from the company's largest shareholder group. The purchase comes one day after the offering closed, extending the group's stake to 15.5 million shares. The warrants carry a $3.50 exercise price and are contingent on shareholder approval of a charter amendment to increase authorized shares — a condition that could create near-term overhang if approved.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 29.6% of the 1645 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PYXS was trading at $2.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $182.7M. The 52-week trading range was $1.03 to $5.55. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.